Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah

Ann Saudi Med. 2022 Jul-Aug;42(4):246-251. doi: 10.5144/0256-4947.2022.229. Epub 2022 Aug 4.

Abstract

Background: Since the occurrence of coronavirus disease in 2019 (COVID-19), the global community has witnessed its exponential spread with devastating outcomes within the general population and specifically within hemodialysis patients.

Objectives: Compare the state of immunity to SARS-CoV-2 among hemodialysis patients and staff.

Design: Cross-sectional study with a prospective follow-up period.

Setting: Hemodialysis centers in Madinah region.

Patients and methods: We prospectively tested for SARS-CoV-2 antibodies in dialysis patients using dialysis centers staff as controls. The participants were tested on four occasions when feasible for the presence of anti-SARS-CoV-2 antibodies. We also analyzed factors that might be associated with seropositivity.

Main outcome measures: SARS-CoV-2 positivity using immunoglobulin G (IgG) levels SAMPLE SIZE: 830 participants, 677 patients and 153 dialysis centers staff as controls.

Results: Of the total participants, 325 (257 patients and 68 staff) were positive for SARS-CoV-2 IgG antibodies, for a prevalence of 38.0% and 44.4% among patients and staff, respectively (P=.1379). Participants with a history of COVID-19 or related symptoms were more likely to have positive IgG (P<.0001). Surprisingly, positivity was also center-dependent. In a multivariable logistic regression, a history of infection and related symptoms contributed significantly to developing immunity.

Conclusion: The high prevalence of SARS-CoV-2 antibody among hemodialysis patients and previously asymptomatic staff suggested past asymptomatic infection. Some centers showed more immunity effects than others.

Limitations: Unable to collect four samples for each participant; limited to one urban center.

Conflict of interest: None.

Publication types

  • Multicenter Study

MeSH terms

  • Antibodies, Viral
  • COVID-19* / epidemiology
  • Cross-Sectional Studies
  • Humans
  • Immunoglobulin G
  • Prevalence
  • Prospective Studies
  • Renal Dialysis
  • SARS-CoV-2*

Substances

  • Antibodies, Viral
  • Immunoglobulin G

Grant support

Funding: None.